BACKGROUND: Conversely to other neurodegenerative diseases (i.e., Alzheimer's disease, AD), sleep in frontotemporal dementia (FTD) has not been studied adequately. Although some evidence exists that sleep-wake disturbances occur in FTD, very little is known regarding sleep macrostructure and/or primary sleep disorders. OBJECTIVE: To investigate these issues in this population and compare them to similar issues in AD and in healthy elderly (HE). METHODS: Twelve drug-naïve behavioral-variant FTD (bvFTD) patients (7 men/5 women) of mean age 62.5 ± 8.6 years were compared to seventeen drug-naïve AD patients (8 men/9 women) of mean age 69.0 ± 9.9 years and twenty drug-naïve HE (12 men/8 women) of mean age 70.2 ± 12.5 years. All participants were fully assessed clinically, through a sleep questionnaire, an interview, and video-polysomnography recordings. RESULTS: The two patient groups were comparably cognitively impaired. However, compared to FTD patients, the AD patients had a statistically significant longer disease duration. Overall, the sleep profile was better preserved in HE. Sleep complaints did not differ considerably between the two patient groups. Sleep parameters and sleep macrostructure were better preserved in AD compared to FTD patients, regardless of primary sleep disorders, which occurred equally in the two groups. CONCLUSIONS: With respect to AD, FTD patients had several sleep parameters similarly or even more affected by neurodegeneration, but in a much shorter time span. The findings probably indicate a centrally originating sleep deregulation. Since in FTD patients sleep disturbances may be obvious from an early stage of their disease, and possibly earlier than in AD patients, physicians and caregivers should be alert for the early detection and treatment of these symptoms.
BACKGROUND: Conversely to other neurodegenerative diseases (i.e., Alzheimer's disease, AD), sleep in frontotemporal dementia (FTD) has not been studied adequately. Although some evidence exists that sleep-wake disturbances occur in FTD, very little is known regarding sleep macrostructure and/or primary sleep disorders. OBJECTIVE: To investigate these issues in this population and compare them to similar issues in AD and in healthy elderly (HE). METHODS: Twelve drug-naïve behavioral-variant FTD (bvFTD) patients (7 men/5 women) of mean age 62.5 ± 8.6 years were compared to seventeen drug-naïve ADpatients (8 men/9 women) of mean age 69.0 ± 9.9 years and twenty drug-naïve HE (12 men/8 women) of mean age 70.2 ± 12.5 years. All participants were fully assessed clinically, through a sleep questionnaire, an interview, and video-polysomnography recordings. RESULTS: The two patient groups were comparably cognitively impaired. However, compared to FTDpatients, the ADpatients had a statistically significant longer disease duration. Overall, the sleep profile was better preserved in HE. Sleep complaints did not differ considerably between the two patient groups. Sleep parameters and sleep macrostructure were better preserved in AD compared to FTDpatients, regardless of primary sleep disorders, which occurred equally in the two groups. CONCLUSIONS: With respect to AD, FTDpatients had several sleep parameters similarly or even more affected by neurodegeneration, but in a much shorter time span. The findings probably indicate a centrally originating sleep deregulation. Since in FTDpatientssleep disturbances may be obvious from an early stage of their disease, and possibly earlier than in ADpatients, physicians and caregivers should be alert for the early detection and treatment of these symptoms.
Authors: Angelica Boeve; Tanis J Ferman; Jeremiah Aakre; Erik St Louis; Michael Silber; Mary Machulda; Julie Fields; Neill Graff-Radford; Michelle Mielke; Yonas Geda; David Jones; Jonathon Graff-Radford; David Knopman; Ronald Petersen; Brad Boeve Journal: Am J Alzheimers Dis Other Demen Date: 2019-02-10 Impact factor: 2.035
Authors: C Liguori; A Romigi; N B Mercuri; M Nuccetelli; F Izzi; M Albanese; G Sancesario; A Martorana; G M Sancesario; S Bernardini; M G Marciani; F Placidi Journal: J Neurol Date: 2014-08-14 Impact factor: 4.849
Authors: Rebekah M Ahmed; Sahar Latheef; Lauren Bartley; Muireann Irish; Glenda M Halliday; Matthew C Kiernan; John R Hodges; Olivier Piguet Journal: Neurology Date: 2015-09-16 Impact factor: 9.910
Authors: Rebekah M Ahmed; Yazi D Ke; Steve Vucic; Lars M Ittner; William Seeley; John R Hodges; Olivier Piguet; Glenda Halliday; Matthew C Kiernan Journal: Nat Rev Neurol Date: 2018-03-23 Impact factor: 42.937
Authors: Jerrah K Holth; Thomas E Mahan; Grace O Robinson; Andreia Rocha; David M Holtzman Journal: Ann Clin Transl Neurol Date: 2017-02-15 Impact factor: 4.511